Last reviewed · How we verify
Rotigotine patch
At a glance
| Generic name | Rotigotine patch |
|---|---|
| Also known as | Neupro patch |
| Sponsor | UCB Pharma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder (PHASE2)
- Adhesion and Safety of Rotigexole Compared to Neupro® (NA)
- Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease (PHASE4)
- A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease (PHASE3)
- Dopaminergic Therapy for Frontotemporal Dementia Patients (PHASE2)
- Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease (PHASE2)
- A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome (PHASE3)
- A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rotigotine patch CI brief — competitive landscape report
- Rotigotine patch updates RSS · CI watch RSS
- UCB Pharma portfolio CI